Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
Artelo Biosciences shares new nonclinical data showing its oral cannabinoid drug ART27.13 matches semaglutide weight loss in obese mice.
Stocks · News reference
Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13Expected to Extend Patent Protection for ART27.13 through 2041SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
Artelo Biosciences Says ART27.13 Cut Body Weight About 20% In Obese Mice, Matching Semaglutide; Combination With Semaglutide Produced About 40% Weight Loss
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times